Directors’ Report Back (from left to right): Dr David Suhy, Mr Carl Stubbings, Mr Iain Ross, Dr John Chiplin, Dr Michael Graham. Front (from left to right): Dr Peter French, Mr Peter Francis, Mr Greg West The Directors of Benitec Biopharma Limited (‘the Company’ or  ‘Benitec’) and its controlled entities (‘the Group’) present their report  for the financial year ended 30 June 2014. The following persons were Directors of Benitec Biopharma Limited  during or since the end of the financial year.  Mr Peter Francis LLB, GRAD DIP (INTELLECTUAL PROPERTY)  Non-Executive Chairman  Appointed 23 February 2006 Mr Peter Francis is a partner at Francis Abourizk Lightowlers (FAL), a  firm of commercial and technology lawyers with offices in Melbourne,  Australia. He is a legal specialist in the areas of intellectual property  and licensing and provides legal advice to a large number of  corporations and research bodies.  Former Directorships of Listed Companies in last three years Xceed Capital Limited. Other Current Directorships of Listed Companies:  None Former Directorships of Listed Companies in last three years Mesoblast Limited (Australia). Other Current Directorships of Listed Companies Stemline Therapeutics, Inc. and Alexza Pharmaceuticals, Inc. Mr Buchi originally trained as a synthetic organic chemist for the  Eastman Kodak Company graduating from Cornell University with  a Bachelor of Arts degree in chemistry. He holds Master’s degree  in management from Kellogg Graduate School of Management at  Northwestern University and is a Certified Public Accountant. Mr. Buchi currently serves as President and CEO and a member of the  Board of Directors of TetraLogic Pharmaceuticals. Mr Buchi is also on  the Board of Directors of Stemline Therapeutics, Inc., Forward Pharma  A/S, Alexza Pharmaceuticals, Inc. and Epirus Biopharmaceuticals. Mr. Buchi served as Chief Executive Officer of Cephalon, Inc. through  its $6.8 billion acquisition by Teva Pharmaceutical Industries in  October 2011. After the acquisition Mr. Buchi served as Corporate  Vice President, Global Branded Products of Teva Pharmaceuticals. Mr.  Buchi joined Cephalon in 1991 and held various positions, including  Chief Operating Officer, Chief Financial Officer and Head of Business  Development prior to being appointed CEO.  Mr Kevin Buchi  BA, MBA, CPA Non-Executive Director Appointed 14 April 2013 NON-EXECUTIVE DIRECTORS Names, qualifications experience and special  responsibilities Page 2 Benitec Biopharma Ltd  Annual Report 2014